Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.58 USD | -1.13% | +7.49% | +65.60% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company sustains low margins.
- With an expected P/E ratio at 122.51 and 74.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+65.60% | 4.3B | C+ | ||
-15.71% | 8.57B | B+ | ||
-9.46% | 2.47B | - | ||
-2.16% | 2.46B | B- | ||
-44.11% | 2.31B | B- | ||
-7.42% | 1.93B | C- | ||
-18.68% | 1.53B | A- | ||
-41.75% | 1.2B | C+ | ||
+11.31% | 1.14B | B+ | ||
+16.15% | 986M | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RDNT Stock
- Ratings RadNet, Inc.